Holen Sie sich die Stockscreener-App
10.10
5.19%
-0.315
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RCEL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$10.41
Offen:
$10
24-Stunden-Volumen:
6,222
Relative Volume:
0.01
Marktkapitalisierung:
$311.12M
Einnahmen:
$72.35M
Nettoeinkommen (Verlust:
$-45.34M
KGV:
-6.4279
EPS:
-1.5705
Netto-Cashflow:
$-32.43M
1W Leistung:
-9.78%
1M Leistung:
+29.87%
6M Leistung:
+101.43%
1J Leistung:
+136.69%
1-Tages-Spanne:
$9.87
$10.07
1-Wochen-Bereich:
$10.11
$11.39
52-Wochen-Spanne:
$3.22
$11.39
Avita Medical Inc Stock (RCEL) Company Profile
Firmenname
Avita Medical Inc
Sektor
Branche
Telefon
661-568-1317
Adresse
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
10.06 | 321.95M | 72.35M | -45.34M | -32.43M | -1.5705 |
ABT
Abbott Laboratories
|
104.70 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.02 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
271.87 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.06 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.01 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Eingeleitet | Northland Capital | Outperform |
| 2025-11-20 | Hochstufung | BTIG Research | Sell → Neutral |
| 2025-08-08 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-12-24 | Eingeleitet | D. Boral Capital | Buy |
| 2024-04-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-27 | Eingeleitet | BofA Securities | Buy |
| 2020-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-03 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Avita Medical Inc Aktie (RCEL) Neueste Nachrichten
Avita Medical Issues 25,213 Unquoted Options Expiring August 2036 Under Employee Incentive Scheme - Kalkine
Precision Trading with Avita Medical Inc. (RCEL) Risk Zones - Stock Traders Daily
564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc. - MarketBeat
Avita Medical Stock Price Forecast. Should You Buy RCEL? - StockInvest.us
RCEL stock gains on fresh price data while Avita Medical readies next steps - ad-hoc-news.de
Gross margin % of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView
Net current asset value per share of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference - Investing News Network
AVITA Medical to Showcase Leadership at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - Kalkine Media
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Balance Sheet – HAM:51KB - TradingView
51KB Stock Price and Chart — HAM:51KB - TradingView
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy - Yahoo Finance
Avita Medical Inc.ADR Peer Comparison – Compare with Others - Value Research
Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $12 - Moomoo
RCEL | Avita Medical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases - Yahoo Finance
AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL) - Seeking Alpha
Avita Medical (RCEL) Stock Forum and Discussion - Moomoo
RCEL Maintained by TD Cowen -- Price Target Raised to $14.00 - GuruFocus
TD Cowen raises Avita Medical stock price target on PermeaDerm data - Investing.com Canada
RCEL Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
AVITA Medical (NASDAQ:RCEL) Raises Full-Year Guidance on Spray-On Skin Adoption - Kalkine Media
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BTIG raises Avita Medical stock price target on positive trial data - Investing.com Canada
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $14 - Moomoo
AVITA Medical (ASX:AVH) Soars 22.73% as Revenue Upgrade and Cash-Flow Target Reset the Conversation - Kalkine
Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
AVITA Medical (ASX:AVH) Jumps 23.18% as Shares Extend a 67% One-Year Recovery - Kalkine
AVITA Medical (ASX: AVH) Reports 70% Cost Advantage for PermeaDerm in Randomized Study - Kalkine
Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint - marketscreener.com
AVITA Medical's PermeaDerm-I Study Reveals 70% Cost Savings Over Cadaveric Allograft with Equivalent Clinical Results - Kalkine Media
AVITA Medical Inc to Host Key Opinion Leader Webinar Transcript - GuruFocus
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes - Investing News Network
RCEL Looks 21.8% Undervalued on GF Value™ - GuruFocus
Avita Medical Says PermeaDerm Study Meets Primary Endpoint, Showing 70% Cost Reduction - marketscreener.com
AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com - Investing.com Canada
A wound matrix cut prep time 96% with outcomes comparable to cadaver grafts - Stock Titan
Avita Medical Raises Full Year 2026 Revenue Guidance - sekbernews.id
Avita Medical Raises Revenue Guidance and Targets Breakeven - sekbernews.id
AVITA Medical Inc Annual Shareholders Meeting Transcript - GuruFocus
AVITA Medical Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
RCEL Q2 2026 Earnings: Narrower Quarterly Loss Beats Estimates; Shares Slip 2%Earnings Quality Analysis - Vinanet
AVITA Medical, Inc. (RCEL) Shareholder/Analyst CallSlideshow (NASDAQ:RCEL) 2026-08-16 - Seeking Alpha
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% - MarketBeat
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds - MarketBeat
RCEL Q2 2026 Earnings: EPS Beat of 14.5% Overshadowed by a 2% Stock DeclineEarnings Expansion Phase - Vinanet
RCEL Q2 2026 Earnings: Loss Narrower Than Expected, Delivering 14.5% EPS SurpriseSpecial Dividend Alert - Vinanet
RCEL Q2 2026 Earnings: Narrower Loss Beats Expectations as Shares Edge LowerEstimate Revision Count - Vinanet
AVITA Medical Inc (RCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript - AOL.com
Finanzdaten der Avita Medical Inc-Aktie (RCEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
1.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):